Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Magnetic Resonance Imaging01:24

Magnetic Resonance Imaging

4.8K
Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique based on a phenomenon of nuclear physics discovered in the 1930s, in which matter exposed to magnetic fields and radio waves was found to emit radio signals. In 1970, a physician and researcher named Raymond Damadian noticed that malignant (cancerous) tissue gave off different signals than normal body tissue. He applied for a patent for the first MRI scanning device in clinical use by the early 1980s. The early MRI...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study.

Urologic oncology·2017
Same author

Diagnostic Accuracy of <sup>64</sup>Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience.

Urology·2017
Same author

The Microbiome of the Prostate Tumor Microenvironment.

European urology·2017
Same author

Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study.

Urologic oncology·2017
Same author

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer.

Clinical genitourinary cancer·2017
Same author

Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.

European urology·2017
Same journal

PROTEUS Trial the Day After: Practice Changing or Premature Escalation?

European urology oncology·2026
Same journal

Overall Survival Benefit from Metformin in High-volume Metastatic Hormone-sensitive Prostate Cancer in STAMPEDE Signals an Opportunity for Metabolically-targeted Therapies in Prostate Cancer.

European urology oncology·2026
Same journal

Dynamic Changes in Tumor Burden in Patients Undergoing PSMA RLT.

European urology oncology·2026
Same journal

Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab.

European urology oncology·2026
Same journal

PROTEUS: A Practice-changing Trial, but Are We Ready to Embrace Perioperative Apalutamide for All High-risk Patients?

European urology oncology·2026
Same journal

Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Real-world Data from a National Early Access Program Registry.

European urology oncology·2026
See all related articles

Related Experiment Video

Updated: May 9, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

106

Variation in Prostate Magnetic Resonance Imaging Performance: Data from the Prostate Biopsy Collaborative Group.

Sunny B Nalavenkata1, Emily Vertosick2, Alberto Briganti3

  • 1Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Urology, Westmead Hospital, The University of Sydney, Sydney, Australia.

European Urology Oncology
|May 3, 2025
PubMed
Summary
This summary is machine-generated.

Prostate MRI quality varies by institution, affecting cancer risk assessment. This variability impacts patient counseling and risk calculators, highlighting the need for standardized multiparametric MRI protocols.

Keywords:
DetectionMultiparametric magnetic resonance imagingPositive predictive valueProstate biopsyRisk stratification

More Related Videos

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.3K
Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease
09:30

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease

Published on: December 18, 2016

19.3K

Related Experiment Videos

Last Updated: May 9, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

106
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.3K
Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease
09:30

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease

Published on: December 18, 2016

19.3K

Area of Science:

  • Radiology
  • Urologic Oncology
  • Medical Imaging Analysis

Background:

  • Prostate magnetic resonance imaging (MRI) quality and reporting are operator-dependent, causing variations in diagnostic accuracy.
  • These variations affect the positive predictive value of imaging across different healthcare sites.
  • Inconsistent results impact crucial aspects of patient care, including counseling, risk modeling, and the reliability of risk calculators.

Purpose of the Study:

  • To assess the variation in Prostate Imaging Reporting and Data System (PI-RADS) score classification across multiple institutions.
  • To evaluate the subsequent probability of detecting grade group (GG) ≥2 prostate cancer based on PI-RADS scores.
  • To identify the impact of inter-institutional variability on clinical decision-making for prostate cancer.

Main Methods:

  • Analysis of data from the Prostate Biopsy Collaborative Group, encompassing 13 sites across North America, Europe, and Asia Pacific (2010-2023).
  • Inclusion of patients who underwent multiparametric MRI (mpMRI) followed by MRI-targeted prostate biopsy with a PI-RADS score ≥3.
  • Logistic regression was used to estimate the risk of PI-RADS 4 or 5 assignment and the associated risk of GG ≥2 disease.

Main Results:

  • A two-fold variation in the probability of PI-RADS 4 or 5 assignment was observed across sites, persisting after risk adjustment (heterogeneity p < 0.001).
  • Significant differences in the absolute risk of GG ≥2 disease for PI-RADS 4 (23%-68%) and PI-RADS 5 (49%-87%) were found (heterogeneity p < 0.001).
  • The study included 7325 biopsies from 7320 unique patients, reflecting typical clinical use of mpMRI despite biopsy limitations.

Conclusions:

  • Wide institutional variation exists in PI-RADS score assignment and the subsequent detection of significant prostate cancer (GG ≥2).
  • This variability directly impacts patient counseling and risk stratification, potentially leading to suboptimal clinical management.
  • Standardization of mpMRI performance and interpretation is essential to improve consistency and reliability in prostate cancer diagnosis and care.